Chapter 60: Adult Neurological Medications

Antimyasthenic agents, particularly acetylcholinesterase inhibitors, address myasthenia gravis by preventing breakdown of acetylcholine at the neuromuscular junction, with critical timing requirements for medication administration and distinction between cholinergic and myasthenic crises during diagnostic testing. Multiple sclerosis treatment utilizes disease-modifying immunomodulators and immunosuppressants to alter disease progression while managing acute relapses and chronic symptoms such as fatigue and neuropathic pain through adjunctive medications. Antiparkinsonian drugs restore dopaminergic and cholinergic balance in the central nervous system, with dopamine agonists requiring careful dietary management regarding protein intake and vitamin supplementation, while anticholinergic agents carry specific contraindications for glaucoma patients. Antiseizure medications suppress abnormal neuronal activity through various mechanisms, with phenytoin requiring precise serum level monitoring, specific intravenous dilution protocols, and management of long-term adverse effects including gingival hyperplasia, while benzodiazepines provide rapid intervention for status epilepticus with available reversal agents. Central nervous system stimulants address attention deficit hyperactivity disorder, narcolepsy, and narcolepsy through cerebral cortex activation, necessitating growth monitoring in pediatric populations and dosing considerations to prevent sleep disruption. Nonopioid analgesics including nonsteroidal anti-inflammatory drugs and acetaminophen provide pain and fever management with distinct toxicity profiles and age-related contraindications, while opioid analgesics and their antagonists require respiratory monitoring and careful consideration of overdose reversal given pharmacokinetic variations. Osmotic diuretics such as mannitol decrease intracranial and intraocular pressure through fluid shifts, demanding vigilant assessment for pulmonary complications and careful preparation to prevent crystallization that compromises therapeutic efficacy.